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Background: Neuropsychological batteries are infrequently used to assess cognitive impairment in multiple sclerosis
because they are time-consuming and require trained personnel. The Symbol Digit Modalities Test (SDMT) is suggested
to be a useful screening tool to measure cognitive impairment in multiple sclerosis patients and is more valid and reliable
over time than the Paced Auditory Serial Addition Test (PASAT). The purpose of this study was to evaluate which of these
tests was more sensitive to cognitive impairment at one-year follow-up.
Methods: A total of 237 patients with relapsing-remitting multiple sclerosis and 57 healthy controls underwent a complete
neuropsychological assessment. One year later, we assessed 196 patients using the Brief Repeatable Battery of
Neuropsychological Tests. We also administered other executive function and prospective memory tests, together
with fatigue and depression questionnaires.
Results: A total of 33.8% of patients were classified as cognitively impaired. The SDMT and the PASAT 3 seconds
test (PASAT3) had a sensitivity of 0.809 and 0.783, respectively, thereby classifying patients as cognitively impaired.
Analysis of 196 patients one year later showed 31.6% had cognitive impairment compared with 27.6% at the first
assessment. The sensitivity to detect cognitive impairment after one year was 0.824 for SDMT and 0.796 for PASAT3.
When the predictors were removed from the comparative standard battery, SDMT still showed a slightly higher sensitivity.
Both SDMT and PASAT3 correlated significantly with all tests, but SDMT showed higher correlation values. Furthermore,
SDMT was completed by all subjects while PASAT3 was completed by 86.9% of patients and 94.7% of controls.
Conclusions: SDMT is simpler to administer than PASAT3 and may be slightly more sensitive to MS cognitive
impairment. It could thus be a suitable test to assess cognitive impairment routinely in people with relapsing-remitting
multiple sclerosis.
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Cognitive impairment (CI) in multiple sclerosis (MS) is
common and disabling [1], affecting recent memory,
sustained attention, verbal fluency, conceptual reasoning,
and visuospatial perception [2]. It is present at all stages
of the disease and limits work and social activities [3].
Because cognitive impairment plays a relevant role in
MS, neuropsychological assessment in routine clinical
practice is needed [1].
Neuropsychological batteries currently available to assess
CI in MS patients are time-consuming and therefore are
not administered to all patients. The Rao Brief Repeatable
Neuropsychological Battery (BRNB) and the Minimal
Assessment on Cognitive Function in MS (MACFIMS)
are most commonly used and take 25–30 and 90 mi-
nutes, respectively, to administer [4,5]. Other batteries
such as the Neuropsychological Screening Battery for
Multiple Sclerosis (NPSBMS), the Screening Examination
for Cognitive Impairment (SEFCI), and the Repeatable
Battery for the Assessment of Neuropsychological Status
(RBANS) take less time to administer, but still require at
least 20 minutes [6]. However, a recently developed bat-
tery, the Brief International Assessment of Cognition
for MS (BICAMS), takes 15 minutes to complete [7].
While the BICAMS was intended to require a minimum
of training, the value of a single test for monitoring cog-
nition in MS remains a valuable goal.
The Symbol Digit Modalities Test (SDMT) has been
proposed for the assessment of CI in MS. SDMT mea-
sures patient attention, concentration and speed of infor-
mation processing [8]. In a study of recently diagnosed
MS patients, Deloire et al. [9] observed that it correctly
classified 75.4% of patients. Parmenter et al. [10] found
that a score of 55 or lower accurately classified CI in MS
patients. Benedict et al. [11] found that the SDMT was
valid for discriminating patients from controls even
when it was administered each month over six months.
In addition, it is simple to administer and takes only five
minutes to complete [12].
Another screening test proposed for use in MS is the
Paced Auditory Serial Addition Test (PASAT), an auditory
test that also measures working memory. It measures the
same cognitive functions as SDMT. PASAT is part of the
Multiple Sclerosis Functional Composite (MSFC), devel-
oped to measure impairment and disability in MS [13],
and it is widely used in clinical research. Despite its exten-
sive use, Brooks et al. showed that results are inadequate
even in young and intellectually active subjects [14].
In a recent study, Sonder et al. [15] reported that
SDMT was more valid and more reliable over time than
the PASAT3 seconds test (PASAT3) as a tool to assess
cognition in MS patients. However, to our knowledge,
no longitudinal, prospective studies have attempted to
predict deficits in cognition.The aim of our study was to evaluate and compare
SDMT and PASAT3 to determine which was more sensi-
tive for the detection of CI when compared with a
complete neuropsychological evaluation in a group of
patients with relapsing-remitting multiple sclerosis
(RRMS) after one year of follow-up.
Methods
Participants
Consecutive patients fulfilling McDonald’s criteria for MS
[16] and attending regular appointments at our MS unit
were recruited from December 2008 to January 2013.
Only patients with RRMS were included. Exclusion cri-
teria were a progressive form of the disease, alcohol, or
drug dependence, presence of a neurological disease other
than MS, history of a medical or psychiatric disorder that
could affect cognitive function, relapse, and corticosteroid
treatment in the past month.
Two hundred and thirty-seven patients who met the
inclusion criteria and 57 healthy controls recruited from
friends and in-law relatives matched by age, gender, and
education level agreed to participate in the study.
Neuropsychological assessment with parallel forms of
the tests was performed in one hundred and ninety-six
patients one year later. All participants gave their written
informed consent before entering the study. The study
was approved by the ethics committee at the Hospital de
la Santa Creu i Sant Pau and performed according to the
Declaration of Helsinki.
Clinical and neuropsychological examination
Neurological examination of all participants was per-
formed by the same experienced MS neurologist. Relapses
were evaluated and disability was assessed to determine
the expanded disability status scale (EDSS) score [17].
Neuropsychological examination was always performed
by the same clinical neuropsychologist. This examination
included the Spanish version of the Brief Repeatable
Battery of Neuropsychological Tests (BRB-N) [18], which
consists of the Selective Reminding Test (SRT) for verbal
memory acquisition and delayed recall, the Spatial Recall
Test (10/36) for visual memory acquisition and delayed
recall, the Symbol Digit Modalities Test (SDMT) and
the Paced Auditory Serial Addition Test (PASAT) for
sustained and complex attention, information process-
ing speed and working memory, and the Word List
Generation (WLG) for verbal fluency.
We used other tests to evaluate executive function: the
Stroop Test [19], the Wisconsin Card Sorting Test
(WCST) [20], and the matrix subtest from the Wechsler
Adult Intelligence Scale (WAIS) [21]. We also assessed
visuospatial functions using the Line Orientation Test
(LO) [22]. For prospective memory, we used the Spanish
translation of the Rivermead Behavioral Memory Test
Table 2 Neuropsychological assessment data for healthy
controls and patients
Healthy controls Patients p value
Mean (SD) Mean (SD)
SRT-Storage 50.9 (8.8) 45.9 (13.6) 0.001*
SRT-Retrieval 43.2 (11.1) 37.1 (13.9) 0.002*
SRT-Delayed 9.7 (1.7) 8.7 (2.4) 0.003*
10/36 22.5 (4.5) 20.6 (5.2) 0.015*
10/36 delayed 8.0 (1.9) 7.3 (2.2) 0.017*
SDMT 63.7 (8.6) 54.3 (13.4) <0.001*
PASAT 3 seconds 48.6 (8.3) 44.8 (11.4) 0.005*
PASAT 2 seconds 39.3 (7.3) 36.2 (10.3) 0.086
Semantic verbal fluency 21.5 (3.8) 19.1 (4.4) <0.001*
Phonetic verbal fluency 17.2 (3.6) 14.7 (4.3) <0.001*
STROOP word 44.7 (9.5) 40.6 (8.7) 0.003*
STROOP color 46.9 (8.0) 42.0 (8.3) 0.001*
STROOP word-color 49.8 (9.2) 44.9 (9.2) 0.001*
STROOP interference 53.3 (9.0) 52.1 (8.2) 0.323
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the Beck Depression Inventory (BDI) [24] and the Fatigue
Severity Scale (FSS) [25].
In accordance with previously published classifications
[15,26], cognitive impairment was defined as a perform-
ance of ≤1.5 standard deviations below control subjects
on two or more tests of the BRB-N. We based the scores
for control subjects on a previously published study
using the Spanish version of the BRB-N [27].
Statistical analysis
We analyzed differences between the control group and
patients regarding demographic variables and cognitive
assessment results using a T test for independent sam-
ples. The same test was also used to compare demo-
graphic characteristics of patients who completed the
PASAT3 with those who did not.
A Pearson correlation coefficient was used to study
the correlation between SDMT and PASAT3 and also
between these two tests and other cognitive variables.
To avoid the influence of outliers, non-parametric corre-
lations (Spearman correlation coefficient) were used. We
applied a multiple linear regression to assess the influ-
ence of variables such as age, fatigue, and depression on
the correlation between the SDMT and the PASAT3 and
the other cognitive tests.
A receiver operating characteristic (ROC) curve for
SDMT and PASAT3 was also generated to obtain sensitiv-
ity and specificity values. The same procedure was followed
to identify which test was more sensitive to detect changes
in cognitive impairment one year later.
Statistical analysis was performed using SPSS 22.0




The group included 237 RRMS patients and 57 healthy
controls. Table 1 shows the demographic and clinical
data for both groups.
Cognitive performance: control group and patients
The control group had significantly higher scores in almost
all cognitive variables assessed in the study (p <0.05),Table 1 Demographic and clinical data of healthy
controls and patients
Healthy controls Patients p value
Gender (male/female) 13/44 80/157 0.090
Age (mean ± SD; years) 40.5 ± 9.4 38.5 ± 10.2 0.198
Education (mean ± SD; years) 14.1 ± 3.4 13.1 ± 4.1 0.095
Disease duration (mean±SD; years) _ 7.4 ± 7.1
EDSS (median, range) _ 1.5 (0 – 6)except for the STROOP interference score and the per-
severative and non-perseverative errors on the WCST.
Scores of self-reported inventories of fatigue and de-
pression were significantly higher in the patient group
(p <0.001). Results are summarized in Table 2.SDMT and PASAT3 comparison
Thirty-one (13.1%) patients and 3 (5.3%) controls were
not willing to perform PASAT3 whereas all participants
completed the SDMT. Patients who did not complete
the test were older and had fewer years of education.
These patients had a longer duration of disease, were
treated with disease modifying therapies for longer pe-
riods, and had higher EDSS scores. No statistically sig-
nificant differences were observed regarding time since
the last relapse. The Beck Depression Inventory score
was higher in the group that did not complete PASAT3.
No significant differences were observed in the Fatigue
Severity Scale score. Table 3 shows the demographic fea-
tures of patients who completed the PASAT3 and those
who did not.WCST perseverative errors 12.2 (17.2) 14.0 (12.5) 0.383
WCST no perseverative errors 18.1 (8.4) 18.8 (9.6) 0.585
WCST categories 5.3 (1.1) 4.8 (1.7) 0.025*
Line orientation test 26.5 (2.6) 25.1 (3.3) 0.004*
WAIS matrix subtest 11.6 (2.5) 10.3 (2.4) <0.001*
RBMT 10.2 (1.3) 9.6 (1.8) 0.021*
FSS 2.2 (0.9) 3.7 (2.0) <0.001*
BDI 3.7 (3.7) 9.1 (7.6) <0.001*
*p < 0.05 was considered statistically significant.
Table 3 Demographic characteristics of patients who
completed the PASAT3 and those who did not
PASAT3 PASAT3 p value
Completed Not completed
Mean (SD) Mean (SD)
Age 38.2 (9.9) 44.4 (9.5) 0.001*
Educational level 13.5 (3.8) 11.3 (4.9) 0.003*
Years of disease evolution 6.7 (6.6) 12.1 (8.3) <0.001*
Total time of treatment 1.6 (2.7) 3.1 (3.2) 0.019*
Time since last relapse 1.4 (2.3) 2.7 (3.6) 0.064
FSS 3.3 (1.8) 3.8 (2.2) 0.297
BDI 7.5 (6.9) 11.4 (8.6) 0.005*
EDSS 1.8 (1.5) 2.4 (1.4) 0.028*
*p < 0.05 was considered statistically significant.
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correlation between PASAT3 and SDMT (r = 0.608,
p <0.001). Both tests showed a significant correlation with
other neuropsychological tests. Nevertheless, although
differences were not statistically significant, correlation
values were higher for SDMT for almost all cognitive tests
and for variables such as fatigue, depression, and EDSS.
When controlling for age, fatigue, and depression, mul-
tiple linear regression showed that coefficients between
SDMT and PASAT3 and other cognitive tests were gener-
ally lower, but again, most were higher for SDMT. All







Semantic verbal fluency 0.375





WCST perseverative errors −0.229
WCST no perseverative errors −0.208
WCST categories 0.220
Line orientation Test 0.331
WAIS matrix subtest 0.417
RIVERMEAD 0.435
*p < 0.05 was considered statistically significant.Sensitivity and specificity of SDMT and PASAT3
In this sample, 33.8% of patients were classified as CI.
According to the definition of CI, SDMT had a sensitiv-
ity of 0.809 and a specificity of 0.662, while PASAT3 had
a sensitivity of 0.783 and a specificity of 0.637. The area
under the curve was 0.811 for SDMT (confidence inter-
val: 0.752–0.870) and 0.761 for PASAT3 (confidence
interval: 0.693–0.830). A cut-off score of 49 for SDMT
classified CI patients with an accuracy of 75%, compared
with a cut-off score of 35 and an accuracy of 73% for
PASAT3. Figure 1 shows the ROC curve.
In the previous analysis, both SDMT and PASAT3
were part of the gold standard for detecting CI in MS
patients. Therefore, we performed another analysis using
the same criteria of failure in at least two tests but
excluding SDMT and PASAT3. We found that 27.4% of
patients were classified as CI. SDMT had a sensitivity of
0.779 and a specificity of 0.692, while PASAT3 had a
sensitivity of 0.727 and a specificity of 0.585. The area
under the curve was 0.809 for SDMT (confidence inter-
val: 0.749–0.870) and 0.700 for PASAT3 (confidence
interval: 0.620–0.779). A cut-off score of 49 for SDMT
classified CI patients with an accuracy of 75%. A cut-off
score of 35 for PASAT3 classified CI patients with an
accuracy of 68%. Figure 2 shows the ROC curve.
One hundred and ninety-six patients were assessed
one year later. The proportion of CI patients in the
baseline assessment in this group was 27.6%. At one-
year follow-up, the proportion of CI subjects increasedPASAT3 when controlling for age, fatigue, depression


















Figure 1 ROC curve for SDMT and PASAT3 (first assessment). Figure 3 ROC curve for SDMT and PASAT3 (second assessment).
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ity of 0.824 and a specificity of 0.741, while PASAT3
had a sensitivity of 0.796 and a specificity of 0.684. The
area under the curve was 0.860 for SDMT (confidence
interval: 0.802–0.918) and 0.772 for PASAT3 (confi-
dence interval: 0.690–0.853). A cut-off score of 49 for
SDMT classified CI patients with an accuracy of 80%
compared with a cut-off score of 35 for PASAT3, which
had an accuracy of 73%. Figure 3 shows the ROC curve.
The same analysis was performed without SDMT and
PASAT3 as part of the gold standard. According to
these criteria, 25% of patients in the baseline assess-
ment in this group were CI. At one-year follow-up, thisFigure 2 ROC curve for SDMT and PASAT3 (first assessment,
excluding SDMT and PASAT).percentage increased to 26%. SDMT had a sensitivity
of 0.800 and a specificity of 0.706, while PASAT3 had a
sensitivity of 0.738 and a specificity of 0.588. The area
under the curve was 0.826 for SDMT (confidence
interval: 0.762–0.891) and 0.697 for PASAT3 (confi-
dence interval: 0.616–0.779). A cut-off score of 49 for
SDMT classified CI patients with an accuracy of 77%,
and a cut-off score of 35 for PASAT3 classified CI
patients with an accuracy of 68%. Figure 4 shows the
ROC curve.
Fatigue and depression are common symptoms in MS
that can affect cognitive function; therefore, we assessed
the sensitivity and specificity of SDMT and PASAT tak-
ing into account these two factors. We found 50% of pa-
tients had symptoms of fatigue and 32.5% had symptoms
of depression. When we compared the fatigue group
(FSS >3) with the non-fatigue group, and the depressed
group (BDI >11) with the non-depressed groups, the
area under the curve was higher for patients without
fatigue or depressive symptoms.
A t-test for repeated measures between the first and
the second evaluation showed that the mean score of
SDMT was 54.5 at the first assessment and 55 at the
second assessment. This difference was not significant
(p = 0.308). The mean score of PASAT3 was 45.2 at the
first assessment and 46.7 at the second. This was statisti-
cally significant (p = 0.011), suggesting a higher learning
effect in PASAT3 than in SDMT.
Discussion
This study showed that both SDMT and PASAT3 could
detect CI in a significant portion of MS patients but sug-
gests that SDMT has a better ability to detect CI after a
year of follow-up. We found significant correlations
Figure 4 ROC curve for SDMT and PASAT3 (second assessment,
excluding SDMT and PASAT).
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memory and executive function. Correlation values were
uniformly higher for SDMT, but were not statistically
significant. Parmenter et al. [10] also reported significant
correlations between SDMT and neuropsychological per-
formance. These data support previous findings regard-
ing the use of these two tests as cognitive assessments to
detect CI in MS.
Previous studies suggested the importance of compar-
ing SDMT and PASAT and defining which of the two
is more specific and sensitive as a measure for CI [10].
According to our definition of CI, sensitivity values for
both SDMT and PASAT3 were similar, although those
for SDMT were slightly higher. A cut-off score of 49 for
SDMT and of 35 for PASAT3 classified CI patients with
an accuracy of 75 and 73%, respectively. Thus, both tests
may be used as screening or monitoring tools because
they measure the speed of information processing and
working memory. The proportion of CI patients in our
sample was similar to that in previous reports [28,29].
The area under the curve was slightly greater for SDMT
than for PASAT3 at the baseline evaluation and after
one year of follow-up. Similar results were obtained
when we analyzed data without SDMT and PASAT3 as
part of the gold standard and when factors such as fatigue
and depression were considered. Although they did not
reach statistical significance, this might indicate that
SDMT performs better than PASAT3 as a test to assess CI.
Our finding that all patients completed SDMT but
that 31 (13.1%) patients were not willing to perform
PASAT3 is in agreement with a previous study that
reported missing values for PASAT3 [15] and another
that reported that 17% of the subjects refused to attemptPASAT [6]. Performance in PASAT3 was influenced by
patient age, duration of the disease, and degree of
disability measured by EDSS. Besides the patients’ basal
characteristics, anxiety may also affect performance in
PASAT. Glanz et al. [30] described an association be-
tween PASAT and patient anxiety and Tombaugh [31]
also reported that PASAT created anxiety and frustra-
tion. In the control group, 3 subjects (5.3%) decided not
to complete PASAT3 even though they completed
SDMT. These data support previous findings in a gen-
eral population regarding difficulties in answering items
in PASAT, even in ideal conditions [14].
When we compared factors related to the administra-
tion of SDMT and PASAT3, we found that SDMT was
completed in a shorter time and that the examples and
the instructions were more easily understood and
followed by patients during the task. Furthermore, previ-
ous studies reported that only minimal training was
needed to master the administration of SDMT [32] and
that it could be completed in a very short time (5 minutes)
[10]. Importantly, no electronic devices are needed to
administer the test.
When administering PASAT3, it was sometimes neces-
sary to repeat the instructions more than once, making
the test longer. Some patients decided not to continue
the test as they complained of difficulties adding the
numbers. An additional inconvenience of PASAT is that
performance is affected by mathematical ability [31,33].
Previous studies showed that SDMT is sensitive for
the detection of cognitive deterioration over time, has a
moderated practice effect [26] and is a reliable test over
multiple test-retest intervals [32]. PASAT showed a tran-
sient practice effect in a 5-year follow-up study, with
relatively stable results after the second evaluation [34].
In our sample, differences in the mean score between
the first and second evaluation were not statistically sig-
nificant by SDMT while they were significant by PASAT3.
These data are in accordance with previous findings in
which patients set up strategies to answer the test, ignor-
ing some items that interfered with the functions it aimed
to measure [33].
A limitation of our study is that the low conversion rate
to CI in MS over a year might have influenced the ability
of SDMT and PASAT3 to detect incident cases of CI.
However, our study has several strengths. Both depression
and fatigue were taken into account, factors that have not
been assessed in previous studies but which may influence
cognitive performance [15]. Furthermore, we selected
RRMS patients so as to assess the utility of SDMT and
PASAT in a less impaired and more homogeneous group
that better represents the initial phases of MS. Finally, we
performed a follow-up visit in our patients one year after
the first evaluation. In previous studies, follow-up visits
were carried out at different times.
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We found that even though the differences in sensitivity
between SDMT and PASAT3 were minor, the differences
were uniformly in the direction of SDMT having slightly
better validity, both at baseline and 1-year follow-up. In
addition, SDMT was easier and faster to administer
compared with PASAT3, and had a greater correlation
with other cognitive tests in the presence of fatigue or
depression.
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